AstraZeneca Results Presentation Deck
Delivering on science-led innovation
Selected key pipeline highlights since Q2 2023 Results
3 Breakthrough Designations (US):
Tagrisso
EGFRM NSCLC (1st-line) (FLAURA2)
Enhertu
HER2-overexpressing advanced or metastatic
colorectal cancer (DESTINY-CRC02)
Enhertu
HER2-expressing tumours (DESTINY-
PanTumour02)
6 regulatory approvals in major markets, including:
Lynparza (JP)
prostate cancer (1st-line) (PROpel)
Enhertu (EU, JP)
HER2m NSCLC (2nd-line+) (DESTINY-Lung02)
Calquence (CN)
CLL (ASCEND)
APPENDIX | Pipeline Highlights
Oncology BioPharmaceuticals Rare Disease
Forxiga (CN)
HFPEF (DELIVER)
Soliris (CN)
neuromyelitis optica spectrum disorder
34 EGFRM= epidermal growth factor receptor-mutated; HER2 = human epidermal growth factor receptor 2; HER2m = human epidermal growth factor receptor 2-mutated; NSCLC = non-small cell lung cancer; CLL = chronic lymphocytic
leukaemia; HFpEF = heart failure with preserved ejection fraction. Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza).View entire presentation